JUN 17, 2019 7:22 AM PDT

Drug Delays Type 1 Diabetes in High Risk Individuals

WRITTEN BY: Nouran Amin

An immunotherapeutic, involving anti-CD3 monoclonal antibody (teplizumab), was seen to slow down the progression to clinical type 1 diabetes in high risk individuals. Findings from the National Institutes of Health-funded research show that clinical type 1 diabetes can be delayed by two or more years for individuals at high risk.

"The difference in outcomes was striking. This discovery is the first evidence we've seen that clinical type 1 diabetes can be delayed with early preventive treatment," said Lisa Spain, Ph.D., Project Scientist from the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), sponsor of TrialNet. "The results have important implications for people, particularly youth, who have relatives with the disease, as these individuals may be at high risk and benefit from early screening and treatment."

These results were published online in The New England Journal of Medicine and presented at the American Diabetes Association Scientific Sessions in San Francisco.

"Previous clinical research funded by the NIH found that teplizumab effectively slows the loss of beta cells in people with recent onset clinical type 1 diabetes, but the drug had never been tested in people who did not have clinical disease," said Kevan C. Herold, M.D., of Yale University, the study's lead author. "We wanted to see whether early intervention would have a benefit for people who are at high risk but do not yet have symptoms of type 1 diabetes."

Type 1 diabetes is a result of the immune system attacking its own insulin-producing cells. Insulin is critical for converting glucose into energy. However, with Teplizumab, it works by targeting the cells that recognize the insulin producing cells as ‘foreign’—lessening the destruction.

Learn more about Type 1 Diabetes:

"While the results are encouraging, more research needs to be done to address the trial's limitations, as well as to fully understand the mechanisms of action, long-term efficacy and safety of the treatment," said Dr. Spain.

"This trial illustrates how decades of research on the biology of type 1 diabetes can lead to promising treatments that have a real impact on people's lives. We're very excited to see the next steps in this research," said Dr. Griffin P. Rodgers, NIDDK Director. "The dedicated researchers, volunteers and families participating in this program make discoveries like this possible."

Source: National Institutes of Health

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 27, 2019
Drug Discovery & Development
NOV 27, 2019
New Painkiller More Effective than Opioids Discovered in Mud
Researchers have discovered a new painkiller dubbed to be as effective as opioids, only minus their disadvantages, from a 16-year old mud sample found near...
DEC 04, 2019
Neuroscience
DEC 04, 2019
Single Dose Ketamine Could Rewire Alcohol, Drug Dependance
Presentation by Tobias Stephenson about previous research exploring ketamine as an addiction treatment.    Researchers at University College Lond...
DEC 20, 2019
Drug Discovery & Development
DEC 20, 2019
Drug Repurposing May Provide Hope for Deadly Childhood Seizure Disorder
The life-threatening and treatment-resistant seizure disorder among children known as the ‘Dravet Syndrome’ may soon have new safe and effectiv...
DEC 21, 2019
Drug Discovery & Development
DEC 21, 2019
Improving Vaccines for Meningitis
Scientists at the University of Nottingham are seeking new ways to improve vaccine use in the protection against the bacterium, Neisseria meningitides that...
DEC 23, 2019
Drug Discovery & Development
DEC 23, 2019
Novel Drug for Treating Insomnia
The U.S. Food and Drug Administration (FDA) has approved DAYVIGO™ (lemborexant) in 5 mg and 10 mg for the treatment of insomnia among adult patients ...
FEB 03, 2020
Drug Discovery & Development
FEB 03, 2020
HIV Viral Structures Improve Therapeutics
Researchers have recently discovered how a powerful class of HIV drugs bind to a key piece of HIV machinery. Their findings, for the first time, shows how ...
Loading Comments...